Close this search box.

Science Spotlight: Lyell’s scaffold for reenergizing CAR T cells; plus Cirrus, Denali and more

ARTICLE | Discovery & Translation

BioCentury’s roundup of translational innovations

By Danielle Golovin, Senior Biopharma Analyst

June 13, 2024 12:07 AM UTC

A subcutaneously injected biodegradable scaffold containing T cell-activating ligands could boost the antitumor efficacy of previously administered CAR T cells.

A team from Harvard University and collaborators at the Dana-Farber Cancer Institute showed that injecting a lymphoma mouse model with a biodegradable scaffold, after administration of CD19-targeted CAR T cells, increased local activation and infiltration of cytotoxic T cells, CAR T cell expansion, antitumor immunity and overall survival compared with the CAR T cells alone.  …